Ynvisible secures SEK 3.0M in Swedish grants for sustainable manufacturing and medical e-paper
What's the deal? Ynvisible InteractiveDealroom has a profile for this one. Try Dealroom →, a Vancouver-based printed e-paper display company, has secured SEK 3.0 million (more than C$400,000) in grants from two Swedish organisations. The funding backs two projects: sustainable battery manufacturing and medical-grade displays.
The larger grant — SEK 2.7 million from VinnovaDealroom has a profile for this one. Try Dealroom →, Sweden's innovation agency — supports the R2R-MICROBAT project, which aims to develop energy-efficient roll-to-roll manufacturing for next-generation batteries. A separate SEK 250,000 grant from Norrköping Science ParkDealroom has a profile for this one. Try Dealroom → funds the MedPrint project, focused on scaling production of e-paper displays for point-of-care diagnostics.
MedPrint targets manufacturing capacity of up to 10 million units per year at Ynvisible's facility in Norrköping, Sweden.
Why now? Demand for low-cost, low-power diagnostic displays is growing as healthcare systems push toward decentralised, point-of-care testing. At the same time, European governments are channelling public funds into sustainable manufacturing and printed electronics — a sector where Sweden is building a regional hub.
"The R2R-MICROBAT project strengthens our position in sustainable manufacturing innovation, while MedPrint expands our presence in the growing medical diagnostics market," said Xu Dang, general manager at Ynvisible Sweden.
What could go wrong? Grant-funded R&D is inherently uncertain. Scaling from lab to 10 million units annually is a significant leap, and the company still needs to prove commercial viability at that volume. Ynvisible is a small-cap stock trading around €0.06 — limited financial resources could slow execution if either project hits snags.
The printed electronics market is also competitive, with larger players investing heavily in flexible and sustainable display technologies.
The signal: Ynvisible sits at the early growth stage according to Dealroom, making public grants from bodies like Vinnova — which operates as an investment fund backing Swedish innovation — critical non-dilutive capital for a company trading at micro-cap valuations. The dual bet on medical displays and sustainable battery manufacturing positions Ynvisible at the intersection of two policy priorities the EU is actively funding, but bridging the gap from grant-backed R&D to commercial-scale production of 10 million units annually remains the make-or-break test for the business.
Read more: FinanzNachrichten.de
